Cargando…
Diagnostic performance of four SARS-CoV-2 antibody assays in patients with COVID-19 or with bacterial and non-SARS-CoV-2 viral respiratory infections
SARS-CoV-2 antibody assays are used for epidemiological studies and for the assessment of vaccine responses in highly vulnerable patients. So far, data on cross-reactivity of SARS-CoV-2 antibody assays is limited. Here, we compared four enzyme-linked immunosorbent assays (ELISAs; Vircell SARS-CoV-2...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189710/ https://www.ncbi.nlm.nih.gov/pubmed/34109500 http://dx.doi.org/10.1007/s10096-021-04285-4 |
_version_ | 1783705541133991936 |
---|---|
author | Huber, Timo Steininger, Philipp Irrgang, Pascal Korn, Klaus Tenbusch, Matthias Diesch, Katharina Achenbach, Susanne Kremer, Andreas E. Werblow, Marissa Vetter, Marcel Bogdan, Christian Held, Jürgen |
author_facet | Huber, Timo Steininger, Philipp Irrgang, Pascal Korn, Klaus Tenbusch, Matthias Diesch, Katharina Achenbach, Susanne Kremer, Andreas E. Werblow, Marissa Vetter, Marcel Bogdan, Christian Held, Jürgen |
author_sort | Huber, Timo |
collection | PubMed |
description | SARS-CoV-2 antibody assays are used for epidemiological studies and for the assessment of vaccine responses in highly vulnerable patients. So far, data on cross-reactivity of SARS-CoV-2 antibody assays is limited. Here, we compared four enzyme-linked immunosorbent assays (ELISAs; Vircell SARS-CoV-2 IgM/IgA and IgG, Euroimmun SARS-CoV-2 IgA and IgG) for detection of anti-SARS-CoV-2 antibodies in 207 patients with COVID-19, 178 patients with serological evidence of different bacterial infections, 107 patients with confirmed viral respiratory disease, and 80 controls from the pre-COVID-19 era. In COVID-19 patients, the assays showed highest sensitivity in week 3 (Vircell-IgM/A and Euroimmun-IgA: 78.9% each) and after week 7 (Vircell-IgG: 97.9%; Euroimmun-IgG: 92.1%). The antibody indices were higher in patients with fatal disease. In general, IgM/IgA assays had only limited or no benefit over IgG assays. In patients with non-SARS-CoV-2 respiratory infections, IgG assays were more specific than IgM/IgA assays, and bacterial infections were associated with more false-positive results than viral infections. The specificities in bacterial and viral infections were 68.0 and 81.3% (Vircell-IgM/IgA), 84.8 and 96.3% (Euroimmun-IgA), 97.8 and 86.0% (Vircell-IgG), and 97.8 and 99.1% (Euroimmun-IgG), respectively. Sera from patients positive for antibodies against Mycoplasma pneumoniae, Chlamydia psittaci, and Legionella pneumophila yielded particularly high rates of unspecific false-positive results in the IgM/IgA assays, which was revealed by applying a highly specific flow-cytometric assay using HEK 293 T cells expressing the SARS-CoV-2 spike protein. Positive results obtained with anti-SARS-CoV-2 IgM/IgA ELISAs require careful interpretation, especially if there is evidence for prior bacterial respiratory infections. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10096-021-04285-4. |
format | Online Article Text |
id | pubmed-8189710 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-81897102021-06-10 Diagnostic performance of four SARS-CoV-2 antibody assays in patients with COVID-19 or with bacterial and non-SARS-CoV-2 viral respiratory infections Huber, Timo Steininger, Philipp Irrgang, Pascal Korn, Klaus Tenbusch, Matthias Diesch, Katharina Achenbach, Susanne Kremer, Andreas E. Werblow, Marissa Vetter, Marcel Bogdan, Christian Held, Jürgen Eur J Clin Microbiol Infect Dis Original Article SARS-CoV-2 antibody assays are used for epidemiological studies and for the assessment of vaccine responses in highly vulnerable patients. So far, data on cross-reactivity of SARS-CoV-2 antibody assays is limited. Here, we compared four enzyme-linked immunosorbent assays (ELISAs; Vircell SARS-CoV-2 IgM/IgA and IgG, Euroimmun SARS-CoV-2 IgA and IgG) for detection of anti-SARS-CoV-2 antibodies in 207 patients with COVID-19, 178 patients with serological evidence of different bacterial infections, 107 patients with confirmed viral respiratory disease, and 80 controls from the pre-COVID-19 era. In COVID-19 patients, the assays showed highest sensitivity in week 3 (Vircell-IgM/A and Euroimmun-IgA: 78.9% each) and after week 7 (Vircell-IgG: 97.9%; Euroimmun-IgG: 92.1%). The antibody indices were higher in patients with fatal disease. In general, IgM/IgA assays had only limited or no benefit over IgG assays. In patients with non-SARS-CoV-2 respiratory infections, IgG assays were more specific than IgM/IgA assays, and bacterial infections were associated with more false-positive results than viral infections. The specificities in bacterial and viral infections were 68.0 and 81.3% (Vircell-IgM/IgA), 84.8 and 96.3% (Euroimmun-IgA), 97.8 and 86.0% (Vircell-IgG), and 97.8 and 99.1% (Euroimmun-IgG), respectively. Sera from patients positive for antibodies against Mycoplasma pneumoniae, Chlamydia psittaci, and Legionella pneumophila yielded particularly high rates of unspecific false-positive results in the IgM/IgA assays, which was revealed by applying a highly specific flow-cytometric assay using HEK 293 T cells expressing the SARS-CoV-2 spike protein. Positive results obtained with anti-SARS-CoV-2 IgM/IgA ELISAs require careful interpretation, especially if there is evidence for prior bacterial respiratory infections. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10096-021-04285-4. Springer Berlin Heidelberg 2021-06-09 2021 /pmc/articles/PMC8189710/ /pubmed/34109500 http://dx.doi.org/10.1007/s10096-021-04285-4 Text en © The Author(s) 2021, corrected publication 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Huber, Timo Steininger, Philipp Irrgang, Pascal Korn, Klaus Tenbusch, Matthias Diesch, Katharina Achenbach, Susanne Kremer, Andreas E. Werblow, Marissa Vetter, Marcel Bogdan, Christian Held, Jürgen Diagnostic performance of four SARS-CoV-2 antibody assays in patients with COVID-19 or with bacterial and non-SARS-CoV-2 viral respiratory infections |
title | Diagnostic performance of four SARS-CoV-2 antibody assays in patients with COVID-19 or with bacterial and non-SARS-CoV-2 viral respiratory infections |
title_full | Diagnostic performance of four SARS-CoV-2 antibody assays in patients with COVID-19 or with bacterial and non-SARS-CoV-2 viral respiratory infections |
title_fullStr | Diagnostic performance of four SARS-CoV-2 antibody assays in patients with COVID-19 or with bacterial and non-SARS-CoV-2 viral respiratory infections |
title_full_unstemmed | Diagnostic performance of four SARS-CoV-2 antibody assays in patients with COVID-19 or with bacterial and non-SARS-CoV-2 viral respiratory infections |
title_short | Diagnostic performance of four SARS-CoV-2 antibody assays in patients with COVID-19 or with bacterial and non-SARS-CoV-2 viral respiratory infections |
title_sort | diagnostic performance of four sars-cov-2 antibody assays in patients with covid-19 or with bacterial and non-sars-cov-2 viral respiratory infections |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189710/ https://www.ncbi.nlm.nih.gov/pubmed/34109500 http://dx.doi.org/10.1007/s10096-021-04285-4 |
work_keys_str_mv | AT hubertimo diagnosticperformanceoffoursarscov2antibodyassaysinpatientswithcovid19orwithbacterialandnonsarscov2viralrespiratoryinfections AT steiningerphilipp diagnosticperformanceoffoursarscov2antibodyassaysinpatientswithcovid19orwithbacterialandnonsarscov2viralrespiratoryinfections AT irrgangpascal diagnosticperformanceoffoursarscov2antibodyassaysinpatientswithcovid19orwithbacterialandnonsarscov2viralrespiratoryinfections AT kornklaus diagnosticperformanceoffoursarscov2antibodyassaysinpatientswithcovid19orwithbacterialandnonsarscov2viralrespiratoryinfections AT tenbuschmatthias diagnosticperformanceoffoursarscov2antibodyassaysinpatientswithcovid19orwithbacterialandnonsarscov2viralrespiratoryinfections AT dieschkatharina diagnosticperformanceoffoursarscov2antibodyassaysinpatientswithcovid19orwithbacterialandnonsarscov2viralrespiratoryinfections AT achenbachsusanne diagnosticperformanceoffoursarscov2antibodyassaysinpatientswithcovid19orwithbacterialandnonsarscov2viralrespiratoryinfections AT kremerandrease diagnosticperformanceoffoursarscov2antibodyassaysinpatientswithcovid19orwithbacterialandnonsarscov2viralrespiratoryinfections AT werblowmarissa diagnosticperformanceoffoursarscov2antibodyassaysinpatientswithcovid19orwithbacterialandnonsarscov2viralrespiratoryinfections AT vettermarcel diagnosticperformanceoffoursarscov2antibodyassaysinpatientswithcovid19orwithbacterialandnonsarscov2viralrespiratoryinfections AT bogdanchristian diagnosticperformanceoffoursarscov2antibodyassaysinpatientswithcovid19orwithbacterialandnonsarscov2viralrespiratoryinfections AT heldjurgen diagnosticperformanceoffoursarscov2antibodyassaysinpatientswithcovid19orwithbacterialandnonsarscov2viralrespiratoryinfections |